CytomX Therapeutics, Inc. (CTMX) Insider Sean A. Mccarthy Sells 9,562 Shares of Stock
CytomX Therapeutics, Inc. (NASDAQ:CTMX) insider Sean A. Mccarthy sold 9,562 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $18.57, for a total transaction of $177,566.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Shares of CytomX Therapeutics, Inc. (CTMX) traded down 4.46% during midday trading on Thursday, hitting $22.06. 484,634 shares of the company’s stock traded hands. The company has a 50 day moving average of $16.92 and a 200 day moving average of $15.62. CytomX Therapeutics, Inc. has a 52 week low of $9.85 and a 52 week high of $24.67. The stock’s market cap is $813.29 million.
CytomX Therapeutics (NASDAQ:CTMX) last announced its earnings results on Monday, August 7th. The biotechnology company reported ($0.69) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.30). CytomX Therapeutics had a negative net margin of 206.33% and a negative return on equity of 84.61%. The firm had revenue of $8.75 million for the quarter, compared to the consensus estimate of $4.95 million. On average, equities analysts forecast that CytomX Therapeutics, Inc. will post ($1.47) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This report was first posted by Marea Informative and is owned by of Marea Informative. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at http://www.mareainformativa.com/cytomx-therapeutics-inc-ctmx-insider-sean-a-mccarthy-sells-9562-shares-of-stock/117433/.
A number of hedge funds have recently made changes to their positions in the stock. California State Teachers Retirement System boosted its stake in CytomX Therapeutics by 27.8% during the second quarter. California State Teachers Retirement System now owns 51,430 shares of the biotechnology company’s stock valued at $797,000 after buying an additional 11,200 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in CytomX Therapeutics by 36.9% during the second quarter. The Manufacturers Life Insurance Company now owns 23,529 shares of the biotechnology company’s stock valued at $365,000 after buying an additional 6,342 shares in the last quarter. Redmile Group LLC boosted its stake in CytomX Therapeutics by 2.4% during the second quarter. Redmile Group LLC now owns 698,392 shares of the biotechnology company’s stock valued at $10,825,000 after buying an additional 16,500 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in CytomX Therapeutics during the second quarter valued at about $174,000. Finally, State Street Corp boosted its stake in CytomX Therapeutics by 58.8% during the second quarter. State Street Corp now owns 446,315 shares of the biotechnology company’s stock valued at $6,914,000 after buying an additional 165,342 shares in the last quarter. 59.97% of the stock is owned by institutional investors and hedge funds.
Several equities analysts have issued reports on CTMX shares. Cowen and Company reissued a “buy” rating on shares of CytomX Therapeutics in a research note on Wednesday, June 28th. BidaskClub raised shares of CytomX Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, July 8th. Cann reissued a “hold” rating on shares of CytomX Therapeutics in a research note on Tuesday, August 8th. Bank of America Corporation reissued a “buy” rating and issued a $30.00 price objective (up from $28.00) on shares of CytomX Therapeutics in a research note on Wednesday, August 9th. Finally, Jefferies Group LLC set a $25.00 target price on shares of CytomX Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 25th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the stock. CytomX Therapeutics currently has a consensus rating of “Hold” and an average target price of $32.67.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Stock Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related stocks with our FREE daily email newsletter.